Nubeqa now available for mHS prostate cancer patients in England
The UK subsidiary of German pharma major Bayer (BAYN: DE) says that Nubeqa (darolutamide) + ADT in combination with docetaxel, for the treatment of National Health Service (NHS) patients with metastatic hormone sensitive prostate cancer (mHSPC), is available immediately in England for eligible patients, following marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) and through a first-in-Europe early access agreement with NHS England.
This follows the initial licence for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in 2020.
The commercial agreement between NHS England and Bayer is the first for a prostate cancer therapy and enables early access for eligible NHS patients in England for this indication while the National Institute for Health and Care Excellence (NICE) completes its ongoing appraisal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze